Drug eluting stents may not be the answer for myocardial bridges.
Although medical treatment is the first-line therapy for myocardial bridges, in some cases revascularization may be required. Percutaneous intervention with bare metal stents is associated with a high restenosis rate. It has been speculated that drug eluting stents might be useful in this setting, although data are limited. We present a patient who suffered multifocal in-stent restenosis after a paclitaxel stent in a myocardial bridge.
Rondan
Juan
J
Lozano
Inigo
I
Avanzas
Pablo
P
Lopez-Palop
Ramon
R
Vegas
Jose M
JM
Moris
Cesar
C
D000789:Angina, Unstable / Q000628:therapy; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D023903:Coronary Restenosis / Q000209:etiology*; D003330:Coronary Vessel Anomalies / Q000628:therapy*; D016503:Drug Delivery Systems; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects*; D015607:Stents / Q000009:adverse effects*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel